Fast, In Vivo Model for Drug-Response Prediction in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Fast, In Vivo Model for Drug-Response Prediction in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Only half of patients with relapsed B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) currently survive with standard treatment protocols. Predicting individual patient responses to defined drugs prior to application would help therapy stratification and could improve survival. With the purp...

Full description

Bibliographic Details
Main Authors: Anton Gauert, Nadine Olk, Helia Pimentel-Gutiérrez, Kathy Astrahantseff, Lasse D. Jensen, Yihai Cao, Angelika Eggert, Cornelia Eckert, Anja I.H. Hagemann
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
pediatric cancer
personalized therapy
BCP-ALL
zebrafish
patient-derived xenograft
Online Access:https://www.mdpi.com/2072-6694/12/7/1883

Internet

https://www.mdpi.com/2072-6694/12/7/1883

Similar Items